iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Analysts

Key Points

• Analysts give iBio a consensus "Buy" rating (one sell, two buy, three strong-buy) with an average 1-year price target of $4.75 and some firms assigning higher targets (JonesTrading at $7.00).
• Shares trade around $2.49 with a market cap of roughly $86M, a negative P/E and a recent quarterly EPS of ($0.09) that missed estimates, underscoring the stock's volatility and risk profile (12‑month range $0.56–$5.60).
• iBio is a biotechnology CDMO focused on biopharmaceutical development and manufacturing, with lead therapeutic candidate IBIO-100 (scleroderma and idiopathic pulmonary fibrosis) and preclinical vaccine programs (IBIO-200/201, IBIO-400).

Shares of iBio, Inc. (NASDAQ:IBIO - Get Free Report) have earned an average recommendation of "Buy" from the six research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $4.75.

Several brokerages recently commented on IBIO. Wall Street Zen upgraded shares of iBio from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Chardan Capital reaffirmed a "buy" rating and issued a $5.00 target price on shares of iBio in a report on Thursday, February 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of iBio in a research report on Monday, December 29th. Lifesci Capital upgraded shares of iBio to a "strong-buy" rating in a report on Thursday, December 18th. Finally, JonesTrading initiated coverage on iBio in a research note on Tuesday, March 3rd. They set a "buy" rating and a $7.00 price target for the company.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new stake in shares of iBio in the 3rd quarter worth approximately $37,000. PFG Investments LLC purchased a new stake in iBio in the 4th quarter worth $41,000. XTX Topco Ltd purchased a new position in shares of iBio during the fourth quarter valued at about $71,000. Persistent Asset Partners Ltd bought a new stake in shares of iBio in the 4th quarter worth about $76,000. Finally, Citadel Advisors LLC bought a new stake in iBio in the third quarter worth about $109,000. Institutional investors own 7.90% of the company's stock.

iBio Stock Performance

Shares of IBIO stock traded up $0.06 on Thursday, hitting $2.49. The stock had a trading volume of 754,806 shares, compared to its average volume of 1,046,711. iBio has a twelve month low of $0.56 and a twelve month high of $5.60. The company has a fifty day simple moving average of $2.37. The firm has a market cap of $86.00 million, a price-to-earnings ratio of -2.49 and a beta of 1.18.

iBio (NASDAQ:IBIO - Get Free Report) last announced its earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01).

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.